HERTFORDSHIRE,
England, and PITTSBURGH, Nov. 2,
2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today
announced that Bill Szablewski,
CFA, has joined the company as Head of Capital Markets, in a new
leadership role working closely with senior leadership. He will be
serving in that same capacity for
VIATRISTM ("Viatris").
At Viatris, Szablewski will be responsible for building Viatris'
brand, reputation and network of relationships in global capital
markets across equity and fixed income investors. Szablewski will
oversee the company's investor relations and treasury functions and
will be a member the Global Finance leadership team reporting to
Sanjeev Narula, the future chief
financial officer of Viatris.
Mylan Executive Chairman Robert J.
Coury said: "We are thrilled to welcome Bill to the team and
believe that his leadership skills and vast expertise in capital
markets and investor relations will be essential as we grow Viatris
and develop as a company."
Szablewski added: "I'm excited to be joining Viatris at this
pivotal time as we prepare to launch a new kind of healthcare
company focused on delivering high-quality medicines to patients in
more than 165 countries. I look forward to telling the Viatris
story while building strong relationships across the investment
community and financial markets globally."
Szablewski has nearly 15 years of experience in the healthcare
industry. Szablewski most recently served as Assistant Treasurer,
Capital Markets at Bristol Myers Squibb (NYSE: BMY). During his
time at Bristol Myers Squibb, his work supported the successful
shareholder vote and debt financing for the Celgene
acquisition. He managed external relationships with banking
counterparties, rating agencies, and fixed income investors and
analysts. Prior to this role, Szablewski served as Director of
Investor Relations, with responsibilities that included supporting
the executive leadership team, developing and executing investor
relations strategy, and global shareholder targeting campaigns. He
is a CFA Charterholder, received his MBA from Drexel University and his bachelor's degree from
Virginia Tech.
About Mylan
Mylan is a global pharmaceutical company
committed to setting new standards in healthcare. Working together
around the world to provide 7 billion people access to high quality
medicine, we innovate to satisfy unmet needs; make reliability and
service excellence a habit; do what's right, not what's easy; and
impact the future through passionate global leadership. We offer a
portfolio of more than 7,500 marketed products around the world,
including antiretroviral therapies on which approximately 40% of
people being treated for HIV/AIDS globally depend. We market our
products in more than 165 countries and territories. We are one of
the world's largest producers of active pharmaceutical ingredients.
Every member of our approximately 35,000-strong workforce is
dedicated to creating better health for a better world, one person
at a time. Learn more at Mylan.com. We routinely post information
that may be important to investors on our website at
investor.mylan.com.
Forward-Looking Statements
This press release includes
statements that constitute "forward-looking statements," including
with regard to the proposed combination of Mylan and Pfizer's
Upjohn business (the "Combination"). Because forward-looking
statements inherently involve risks and uncertainties, actual
future results may differ materially from those expressed or
implied by such statements. Factors that could cause or contribute
to such differences include, but are not limited to the completion
of the Combination on the anticipated timeline or at all, and the
achievement of the anticipated benefits of the Combination; the
potential widespread and highly uncertain impact of public health
outbreaks, epidemics and pandemics, such as the COVID-19 pandemic;
any changes in, interruptions to, or difficulties with Mylan's or
its partners' ability to develop, manufacture, and commercialize
products; the effect of any changes in Mylan's or its partners'
customer and supplier relationships and customer purchasing
patterns; other changes in third-party relationships; the impact of
competition; changes in the economic and financial conditions of
the businesses of Mylan or its partners; the scope, timing, and
outcome of any ongoing legal proceedings and the impact of any such
proceedings on Mylan's or its partners' business; any regulatory,
legal, or other impediments to Mylan's or its partners' ability to
bring products to market; actions and decisions of healthcare and
pharmaceutical regulators, and changes in healthcare and
pharmaceutical laws and regulations, in the United States and abroad; Mylan's and its
partners' ability to protect intellectual property and preserve
intellectual property rights; risks associated with international
operations; other uncertainties and matters beyond the control of
management; and the other risks detailed in Mylan's filings with
the Securities and Exchange Commission. Mylan undertakes no
obligation to update these statements for revisions or changes
after the date of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mylan-announces-appointment-of-experienced-pharmaceutical-executive-bill-szablewski-as-head-of-capital-markets-for-viatris-301164592.html
SOURCE Mylan N.V.